Advances in Prostate Cancer Treatment: Exploring Molecular Targets and New Strategies in Castration-Resistant Disease

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Castration-resistant prostate cancer (CRPC) is a significant clinical challenge.
• Tumor progression occurs despite androgen deprivation therapy (ADT).
• Resistance mechanisms are diverse, involving AR pathway alterations and bypass signaling.

Purpose of the Study:

• To review recent advances in understanding CRPC resistance mechanisms.
• To highlight emerging therapeutic strategies targeting these pathways.
• To discuss novel treatment approaches for advanced prostate cancer.

Main Methods:

• Literature review of recent scientific publications.
• Synthesis of data on molecular mechanisms of resistance.
• Analysis of emerging therapeutic strategies and clinical trials.

Main Results:

• Identified key resistance mechanisms: AR amplification, splice variants, PI3K/AKT/mTOR, immune checkpoints, neuroendocrine differentiation.
• Highlighted novel therapies: next-generation AR inhibitors (e.g., darolutamide), PARP inhibitors, PSMA-targeted radioligand therapy.
• Discussed emerging targets like heat shock response (HSF1 inhibitors).

Conclusions:

• Targeting molecular heterogeneity is crucial for effective CRPC treatment.
• Personalized treatment strategies are essential for improving survival and quality of life.
• Ongoing research offers hope for more effective therapies for advanced prostate cancer.